2C-T-21 (2,5-dimethoxy-4-(2-fluoroethylthio)phenethylamine) is one of the most obscure and least-tested compounds in Alexander Shulgin's PiHKAL catalog -- a psychedelic phenethylamine that combines the already-dangerous thio-substitution of the 2C-T family with a fluorinated ethyl chain whose metabolic fate in humans is essentially unknown. Listed as entry #42 in PiHKAL (1991), Shulgin documented an active dose of 8-12 mg, a duration of 7-10 hours, and reported the experience favorably. But Shulgin's bioassay group numbered a handful of people, and 2C-T-21 never received the wider testing that even its more famous siblings 2C-T-2 and 2C-T-7 got before things went wrong.
What makes 2C-T-21 pharmacologically notable is the fluorine atom at the terminal position of the ethyl chain on the thio group. Fluorine substitution in medicinal chemistry typically increases metabolic stability -- the carbon-fluorine bond is one of the strongest in organic chemistry, resisting the CYP450 oxidation that normally breaks down drug molecules. In the context of a thio-substituted phenethylamine, this means 2C-T-21 may be cleared more slowly than its non-fluorinated cousins, potentially extending the window of MAO interaction and serotonin toxicity risk. There is also a theoretical concern, raised by researchers but never tested in 2C-T-21 specifically, that fluoroethyl groups can be metabolized to fluoroacetaldehyde -- a precursor to fluoroacetate, the compound used in the rodenticide 1080. Whether this metabolic pathway is relevant at 2C-T-21's typical doses is entirely unknown.
The handful of experience reports that exist describe a contemplative, moderately visual psychedelic experience with warm, autumnal visual character, minimal body load compared to 2C-T-2 and 2C-T-7, and a philosophical headspace that rewards solitude and reflection. The duration is long -- 7-10 hours with a gradual, steady plateau. Those who have tried it generally describe it as one of the gentler thio-2C experiences. But "gentle" is a description of subjective effects at reported doses in a tiny number of people, not a statement about safety. 2C-T-21 carries every toxicological concern of the 2C-T family -- MAO interaction, serotonin toxicity risk, cardiovascular effects, individual variability -- plus the additional unknowns introduced by fluorine substitution. It has no meaningful safety database, no published pharmacokinetic data, and no clinical characterization. It is, in the most literal sense, an experiment in progress.
Safety at a Glance
High Risk- The Fundamental Problem: No Data
- Inherited Risks from the 2C-T Family
- Toxicity: The Unknown Risk Profile 2C-T-21's toxicity is characterized primarily by what is not known rather than what is. No h...
- Overdose risk: Assessing a 2C-T-21 Emergency There is no published clinical data on 2C-T-21 overdose or adverse ...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 10 hrs – 12 hrsHow It Feels
The onset is unhurried and methodical. An hour or more passes before anything becomes clearly perceptible -- a gradual brightening of the visual field, a subtle shift in cognitive texture, a warming in the chest that could almost be mistaken for the psychosomatic anticipation of any come-up. The body registers the change before the mind does: a gentle warmth, the faintest stirring in the stomach (less aggressive than 2C-T-2 or 2C-T-7, by most accounts), and a quiet energy that accumulates without urgency. There is none of the electric rush of a phenethylamine like 2C-B and none of the anxious body load of the heavier thio compounds. It feels, in the early stages, like a slow tide coming in.
By the second hour, the experience has established itself with a character that feels distinctly its own. The visual field fills with soft, flowing geometry -- organic patterns overlaying surfaces with the gentleness of watercolors rather than the hard precision of synthetic visuals. The color palette is remarkably specific, appearing across multiple independent reports: deep golds, burnt oranges, rich greens, amber tones. The world takes on the quality of late-afternoon autumn light, warm and elegiac and slightly dreamlike. Surfaces breathe slowly. Objects seem simultaneously more real and more symbolic, as though you are seeing them both literally and metaphorically at the same time. Closed-eye visuals are present but undemanding -- slowly evolving landscapes of color and form that you can engage with or ignore.
The headspace is the defining feature. Where 2C-T-7 pulls you inward with emotional force and 2C-T-2 opens you socially, 2C-T-21 sits you down in a philosophical armchair and lets you think. The introspection is measured and unhurried, turning toward broad questions -- meaning, connection, purpose, the structure of experience itself -- rather than drilling into personal psychological material. There is a contemplative quality that experienced psychonauts have compared to a slow, steady dose of mescaline: the kind of headspace that rewards sitting quietly with a cup of tea and looking out a window for an hour. Emotional tone is warm and stable, anchored against anxiety or difficult turns by a steady contentment that runs through the experience like a bass note. Music is gently enhanced. Solitude feels as natural as company.
The duration is the practical defining feature. Effects sustain for eight to twelve hours, with a long, gradual plateau that neither spikes dramatically nor fades prematurely. The slow decline is smooth, effects tapering over the final hours like a long sunset. There is no harsh landing, no grinding residual stimulation. Fatigue may settle in toward the end, and sleep is not easy until the effects have fully cleared. The aftermath is clean -- a mild afterglow of reflective clarity that can persist into the following day, and a sense of having spent extended time in a contemplative space that was peaceful rather than challenging.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(26)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Changes in felt bodily form— Changes in felt bodily form is the experience of one's body feeling as though it has altered its phy...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Diarrhea— Diarrhea is the occurrence of frequent, loose, or watery bowel movements as a side effect of certain...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Muscle cramp— Muscle cramps are sudden, involuntary, and often painful contractions of muscles that occur as a sid...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Stomach bloating— Stomach bloating is the uncomfortable distension of the abdomen resulting from gas accumulation, flu...
- Stomach cramp— Stomach cramps are sharp, intermittent pains in the abdominal region that can occur when psychoactiv...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Watery eyes— Excessive tear production causing overflow tearing and blurred vision, commonly occurring during opi...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(13)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(13)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(1)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(2)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
2C-T-21's psychedelic effects are presumed to arise from partial agonism at serotonin 5-HT2A receptors, consistent with all members of the 2C family. The 2-fluoroethylthio substituent at C4 provides receptor affinity in the range of its thio-substituted cousins, with an active dose of 8-12 mg placing it among the more potent members of the series. Additional activity at 5-HT2C receptors is expected based on structural analogy.
The Fluorine Question
The terminal fluorine on the ethyl chain introduces pharmacological considerations unique to 2C-T-21:
- Metabolic resistance -- The carbon-fluorine bond is among the strongest single bonds in organic chemistry (bond dissociation energy ~485 kJ/mol). Fluorination of drug molecules is a standard medicinal chemistry technique for increasing metabolic half-life because CYP450 enzymes cannot easily cleave C-F bonds. In 2C-T-21, this likely means the compound resists hepatic oxidation more effectively than the non-fluorinated 2C-T-2, potentially extending duration of action and the window during which MAO interaction is pharmacologically active
- Fluoroacetaldehyde pathway -- Under certain metabolic conditions, terminal fluoroethyl groups can undergo oxidative deamination or CYP-mediated cleavage to produce fluoroacetaldehyde, which is further oxidized to fluoroacetate. Fluoroacetate (known commercially as compound 1080) is a potent inhibitor of the citric acid cycle enzyme aconitase, causing lethal mitochondrial poisoning at milligram doses. Whether this metabolic pathway is engaged at the low doses of 2C-T-21 that humans have taken is completely unknown -- it may be negligible, or it may contribute to the fatigue and malaise some users report. No published research addresses this question
MAO Interaction
Like all thio-substituted 2C compounds, 2C-T-21 carries the presumption of monoamine oxidase substrate interaction. The sulfur atom creates the same mechanistic basis for autoinhibited metabolism, individual variability in clearance, and amplified serotonin toxicity in combination with serotonergic substances that has caused fatalities with 2C-T-2 and 2C-T-7. The fluorine's effect on this interaction -- whether it increases or decreases the MAO substrate activity -- is uncharacterized.
The Data Problem
2C-T-21 has no published human pharmacokinetic data, no formal receptor binding studies specific to the compound, no animal toxicology beyond Shulgin's qualitative observations, and no dose-response characterization beyond a handful of self-reports. Every pharmacological statement about this compound is extrapolated from structural analogy and first-principles chemistry. This is not a well-understood drug with known risks -- it is a poorly understood drug with unknown risks layered on top of a family with established lethal potential.
Detection Methods
Urine Detection
2C-T-21 is not specifically targeted by standard immunoassay-based urine drug panels. However, because 2C-x phenethylamines share structural features with amphetamines, they may trigger false positives on amphetamine immunoassays in some cases. The likelihood of cross-reactivity depends on the specific immunoassay manufacturer and the antibody selectivity used. Urine detection windows for 2C-T-21 are estimated at 24 to 72 hours following ingestion when analyzed by LC-MS/MS methods, though limited pharmacokinetic data exists for many 2C-x compounds.
Blood and Serum Detection
Blood detection windows for 2C-T-21 are approximately 6 to 24 hours after oral administration. Peak plasma concentrations typically occur 1 to 3 hours post-ingestion. The relatively short half-lives of most 2C-x phenethylamines mean that blood testing must be performed promptly to capture detectable concentrations. LC-MS/MS is the only reliable method for quantitative blood analysis.
Standard Drug Panel Inclusion
2C-T-21 is NOT specifically included on standard 5-panel, 10-panel, or 12-panel drug screens. The primary concern for individuals undergoing routine screening is the potential for amphetamine cross-reactivity on immunoassay-based panels. If a presumptive positive for amphetamines occurs, confirmatory testing by GC-MS or LC-MS/MS would not confirm amphetamine and the result would be reported as negative unless the laboratory specifically tests for 2C-x compounds. Most routine laboratories do not include 2C-x phenethylamines in their confirmatory panels.
Confirmatory Methods
Definitive identification of 2C-T-21 requires LC-MS/MS or GC-MS with appropriate reference standards. Some forensic toxicology laboratories include 2C-x phenethylamines in their extended novel psychoactive substance panels. Immunoassay cross-reactivity alone is insufficient for confirmation and would be resolved by standard confirmatory procedures. Quantitative analysis typically requires specific method development as these compounds are not part of routine clinical chemistry workflows.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Marquis reagent is a primary screening tool for 2C-T-21. The Marquis reagent produces a variable brown to green reaction with 2C-T-21. The Mecke reagent may provide additional color reactions that help differentiate between specific 2C-x variants. The Ehrlich reagent shows no reaction with 2C-x phenethylamines, which can help distinguish them from tryptamines and lysergamides. The Mandelin reagent may produce green to brown reactions depending on the specific compound. Using multiple reagents in combination provides the most reliable field identification, though reagent testing cannot determine purity or dosage.
Interactions
| Substance | Status | Note |
|---|---|---|
| 2-Aminoindane | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FEA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2,5-DMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1B-LSD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-AL-LAD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-LSD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-MiPLA | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
2C-T-21 was synthesized by Alexander Shulgin as part of his extended exploration of thio-substituted phenethylamines -- a series that systematically varied the alkyl group attached to the sulfur atom at the 4-position of the 2,5-dimethoxyphenethylamine scaffold. The compound appears as entry #42 in PiHKAL: A Chemical Love Story (1991). Shulgin's innovation with 2C-T-21 was the introduction of a fluorine atom at the terminal position of the ethyl chain -- a modification drawn from medicinal chemistry's well-established use of fluorination to modulate drug metabolism and potency.
Shulgin documented an active dose of 8-12 mg, a duration of 7-10 hours, and described the experience in generally positive terms. However, 2C-T-21 received notably less attention in PiHKAL than its siblings 2C-T-2 and 2C-T-7, and Shulgin's commentary suggested it was more of a structural exploration -- testing what fluorination did to the thio series -- than a compound he considered particularly remarkable for its subjective effects.
Through the 1990s and early 2000s, 2C-T-21 existed on the extreme periphery of the research chemical market. A small number of vendors offered it briefly, and a scattering of experience reports appeared on Erowid and early psychedelic forums. It never achieved the popularity of 2C-T-7 or even 2C-T-2, in part because supply was limited and in part because the compound existed in the shadow of more famous and more readily available members of the series.
The 2000-2001 fatalities associated with 2C-T-7 and 2C-T-2 triggered broad scheduling actions against thio-substituted phenethylamines. 2C-T-21 was swept into these actions despite having no independently documented adverse events. In the UK, it became a Class A substance under the phenethylamine catch-all clause. In Canada, it was placed in Schedule III as of October 2016. In Germany, it was controlled under the NpSG (Neue-Psychoaktive-Substanzen-Gesetz) as of November 2016. In the United States, while not explicitly named in the schedules, it could be prosecuted under the Federal Analogue Act as a structural analog of scheduled 2C-T compounds. Austria, Switzerland, and most other jurisdictions with analog or blanket phenethylamine legislation also effectively prohibited it.
The result is that 2C-T-21 was scheduled before it was studied. It exists in the pharmacological literature primarily as a data point in Shulgin's structure-activity relationship work, not as a compound with independent characterization. Whatever it might have revealed about the effects of fluorination on thio-phenethylamine pharmacology remains unknown -- a question that regulatory action foreclosed before research could address it.
Harm Reduction
The Fundamental Problem: No Data
2C-T-21 has effectively no safety database. Unlike 2C-T-2 and 2C-T-7, which at least accumulated enough adverse event reports to characterize their risk profiles, 2C-T-21 is so rarely used that even if it were causing harm, the events would likely go unrecognized or unreported. Using this compound means accepting risks you cannot quantify because the information does not exist.
Inherited Risks from the 2C-T Family
Everything known about thio-substituted 2C compounds applies to 2C-T-21:
- MAO substrate interaction creating unpredictable metabolism
- Serotonin toxicity risk, especially in combination with serotonergic substances
- Cardiovascular stimulation (tachycardia, hypertension, vasoconstriction)
- Dramatic individual variability in response based on MAO enzyme expression
- Every combination warning that applies to 2C-T-2 and 2C-T-7 applies here
Additional Unknowns from Fluorine Substitution
The fluoroethyl group introduces metabolic pathways not present in other 2C-T compounds. Whether fluoroacetate metabolites are produced at relevant levels is unknown. Whether the increased metabolic stability of the C-F bond extends duration in a clinically significant way is unknown. Whether it changes the MAO interaction profile is unknown. Each unknown is an additional reason not to use this compound.
Combinations That Must Be Avoided
- MAOIs (all forms -- prescription, herbal, dietary): Absolutely contraindicated
- SSRIs and SNRIs: Contraindicated
- MDMA and other serotonin releasers: Absolutely contraindicated
- DXM (dextromethorphan): Absolutely contraindicated
- Triptans: Contraindicated
- Lithium: Contraindicated
- Tramadol: Contraindicated
- Stimulants: Contraindicated
If Someone Uses This Compound
- Treat every reported dose guideline as unverified. Shulgin's 8-12 mg range was established with a handful of people
- Start well below reported thresholds. 4-5 mg would be a cautious first exploration
- Milligram-accurate scales are non-negotiable at this potency
- Sober sitter for the full 12+ hour duration
- Immediate access to emergency medical services
- Do not combine with any other substance
- Do not redose. The slow onset (60+ minutes) will tempt stacking
Serotonin Syndrome Recognition
Identical protocol to all thio-2C compounds:
- Mild: Restlessness, dilated pupils, sweating, rapid heart rate
- Moderate: Clonus (involuntary rhythmic jerking), tremor, fever, hyperreflexia
- Severe: Rigid muscles, temperature above 41°C, seizures, delirium, cardiovascular instability
Call emergency services at any sign of moderate symptoms. Do not wait.
Toxicity & Safety
The Unknown Risk Profile
2C-T-21's toxicity is characterized primarily by what is not known rather than what is. No human pharmacokinetic data has been published. No formal dose-response studies exist. No animal toxicology beyond Shulgin's qualitative observations has been conducted. No adverse event case reports specific to 2C-T-21 appear in the medical literature. This absence of data should not be interpreted as evidence of safety -- it reflects the compound's extreme rarity of use, not a clean safety record.
Inherited 2C-T Family Toxicity
By structural analogy, 2C-T-21 carries every toxicological concern documented for the broader thio-2C family:
- MAO interaction and serotonin toxicity: The sulfur atom in the 4-substituent creates the same monoamine oxidase substrate interaction that has caused fatalities with 2C-T-2 and 2C-T-7. At high doses or in combination with serotonergic substances, this can produce serotonin syndrome -- progressing from agitation and hyperthermia to seizures, cardiovascular collapse, and death
- Cardiovascular effects: Tachycardia, hypertension, and vasoconstriction are documented across the thio-2C class and are presumed to apply to 2C-T-21
- Individual variability: MAO enzyme expression varies genetically across individuals, making dose-response prediction unreliable for any thio-substituted compound
The Fluoroacetate Question
The fluoroethyl group on 2C-T-21's thio substituent introduces a theoretical toxicity pathway not present in other 2C compounds. Terminal fluoroethyl groups can undergo metabolic oxidation to fluoroacetaldehyde, which is further converted to fluoroacetate -- a potent inhibitor of the citric acid cycle enzyme aconitase. Fluoroacetate (compound 1080) causes lethal energy failure in tissues with high metabolic demand: the heart, brain, kidneys, and gonads.
Key considerations:
- Whether this metabolic pathway is engaged at 2C-T-21's typical doses (8-12 mg) is completely unknown
- The toxic dose of sodium fluoroacetate in humans is approximately 2-10 mg/kg -- orders of magnitude above what could be generated from a single 2C-T-21 dose, assuming full conversion (which is unlikely)
- However, even sub-toxic levels of fluoroacetate could theoretically contribute to the fatigue, malaise, or organ stress reported by some users
- A couple referenced in Myron Stolaroff's work became "convinced that it is toxic" after their experience -- an anecdote, not evidence, but notable given the theoretical mechanism
The honest assessment is that no one knows whether the fluoroacetate pathway matters for 2C-T-21. It may be entirely irrelevant. It may contribute marginally to adverse effects. Without targeted metabolic studies, the question remains open.
No Safety Database to Draw From
With 2C-T-2 and 2C-T-7, the harm reduction community at least has adverse event reports, autopsy data, and toxicological analyses to characterize the risk profile. With 2C-T-21, even that minimal evidence base does not exist. Using this compound means accepting entirely unquantified risk from a family with established lethal potential, compounded by a unique structural modification whose metabolic consequences are uncharacterized.
Absolute Contraindications
Addiction Potential
2C-T-21 has no meaningful addiction potential. As a serotonergic psychedelic operating through 5-HT2A agonism, it lacks the dopaminergic reinforcement mechanisms that drive compulsive use of addictive substances. The experience is long (7-10 hours), physically taxing, and contemplative in character -- not the profile of a substance people reach for impulsively or frequently. Tolerance develops rapidly after a single dose, preventing meaningful effects from redosing within 48-72 hours. Full tolerance reset is estimated at 7-14 days based on the behavior of related compounds. Cross-tolerance exists with all serotonergic psychedelics. No physical dependence, withdrawal syndrome, or compulsive use pattern has been reported. The compound is so rarely used that even if subtle reinforcement patterns existed, there would be insufficient data to detect them. The risk with 2C-T-21 is not addiction but acute harm -- an uncharacterized toxicity profile from a compound family with established lethal potential, compounded by unique structural features whose metabolic consequences are unknown.
Overdose Information
Assessing a 2C-T-21 Emergency
There is no published clinical data on 2C-T-21 overdose or adverse events. Emergency response must be guided by protocols for thio-substituted 2C compounds generally, with additional vigilance for signs that could indicate fluoroacetate-related toxicity.
Signs of serotonin syndrome (treat as medical emergency):
- Body temperature above 39°C (102°F) and rising
- Sustained heart rate above 150 bpm
- Muscle rigidity, clonus (involuntary rhythmic jerking), sustained tremor
- Agitation progressing to confusion or delirium
- Seizure of any duration
- Profuse sweating with inability to thermoregulate
Signs that may indicate broader metabolic toxicity:
- Chest pain or irregular heartbeat (cardiac tissue is vulnerable to both serotonin toxicity and theoretical fluoroacetate-mediated energy failure)
- Persistent, severe fatigue disproportionate to the psychedelic experience
- Oliguria (reduced urine output) -- potential indicator of renal stress
- Prolonged confusion beyond expected psychedelic effects duration
Emergency Response
- Call emergency services. State: "Adverse reaction to a serotonergic research chemical with potential serotonin syndrome." Provide the substance name (spell it: "2C-T-21, a fluorinated thio-phenethylamine"), dose, time of ingestion, and any other substances taken. Emergency physicians may not be familiar with this compound -- the critical information is that it is serotonergic with MAO-interacting properties
- Begin cooling immediately. Hyperthermia is the proximate killer in serotonin syndrome. Remove excess clothing. Apply ice packs to armpits, groin, and neck. Mist skin with water and fan aggressively. Evaporative cooling is the most effective field technique
- Benzodiazepines for agitation and seizures. Diazepam or lorazepam if available. Do not use antipsychotics -- they can worsen serotonergic crises and some (haloperidol) lower the seizure threshold
- Monitor continuously. Airway, breathing, pulse. If consciousness is lost, recovery position. Be prepared for CPR
- Record timeline. Time of ingestion, dose, route, other substances, sequence of symptom development. This information is critical for hospital management
Managing Psychological Distress
If the person is physically stable but experiencing intense anxiety, fear, or perceptual disturbance:
- Move to a calm, quiet space with minimal stimulation
- Speak slowly and clearly. Use their name. Maintain gentle eye contact
- Anchor them with simple physical grounding: hands on a cool surface, feet on the floor, cold water on wrists
- Remind them that the effects are caused by a substance and will end. "This is a drug effect. It is temporary. You are safe."
- Do not leave them alone for any duration
- If distress does not improve within 30 minutes, or if reality testing is impaired (they cannot distinguish hallucinations from reality, or they express intent to harm themselves), seek emergency medical attention
Good Samaritan protections apply. Never delay calling for help because of legal concerns.
Tolerance
| Full | almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
Austria: 2C-T-21 is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Canada: As of October 31st, 2016; 2C-T-21 is a controlled substance (Schedule III) in Canada.
Germany: 2C-T-21 is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable. The legislator considers it possible that orders of 2C-T-21 are punishable as an incitement to place it on the market.
Switzerland: 2C-T-21 can be considered a controlled substance as a defined derivative of Phenethylamine under Verzeichnis E point 130. It is legal when used for scientific or industrial use.
United Kingdom: 2C-T-21 is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.
United States: 2C-T-21 is technically not scheduled in the United States, but could be considered an analogue of 2C-T or 2C-T-7 and may therefore be considered a Schedule I drug under the Federal Analogue Act.
Responsible use
Research chemical
2C-T-7
2C-T-21 (Wikipedia)
2C-T-21 (Erowid Vault)
2C-T-21 (PiHKAL / Isomer Design)
Experience Reports (1)
Tips (3)
Start with a low dose of 2C-T-21 if it is your first time. You can always take more next time but you cannot take less once ingested. The difference between a comfortable and an overwhelming experience can be surprisingly small.
Keep a benzodiazepine like alprazolam on hand as an emergency trip abort tool when using 2C-T-21. Even just knowing you have one available provides psychological reassurance. It will not fully end the trip but significantly reduces intensity.
Have a trip sitter present, ideally someone with psychedelic experience. They should remain calm and reassuring without being intrusive. A good sitter can make the difference between a challenging experience and a genuine crisis.
See Also
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 2C-T-21 - TripSit Factsheet
TripSit factsheet for 2C-T-21
tripsit - 2C-T-21 - Wikipedia
Wikipedia article on 2C-T-21
wikipedia